REG - Hutchmed China Ltd - Director’s Share Dealing

HUTCHMED (China)Announcement

14/09/2023 09:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230914:nRSN4497Ma&default-theme=true

RNS Number : 4497M  Hutchmed (China) Limited  14 September 2023

Director's Share Dealing

 

Hong Kong, Shanghai & Florham Park, NJ - Thursday, September 14, 2023:
HUTCHMED (China) Limited ("HUTCHMED (https://www.hutch-med.com/) " or the
"Company") (Nasdaq/AIM: HCM; SEHK:13) has received notifications that the
spouse of Mr Graeme Jack, Independent Non-executive Director, sold a total of
3,000 American Depositary Shares of the Company ("ADSs", each representing
five Ordinary Shares of US$0.10 each of the Company) at a price of US$14.70
per ADS on September 12, 2023.

 

Following the above sale of 3,000 ADSs, the holding of Mr Jack is 17,339 ADSs
(Note), representing approximately 0.01% of the current issued share capital
of the Company.

 

Note: 17,339 ADSs included (i) 9,128 ADSs currently held by Mr Jack and (ii)
8,211 ADSs as beneficiary of a trust under long term incentive plan.

 

The notifications set out below are provided in accordance with the
requirements of the EU Market Abuse Regulation.

 

 

 1    Details of the person discharging managerial responsibilities/person closely
      associated

 a)   Name                                                          Ms Debbie Sue Chung

 2    Reason for the notification

 a)   Position/status                                               Spouse of Mr Graeme Jack, Independent Non-executive Director

 b)   Initial notification/Amendment                                Initial notification

 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor

 a)   Name                                                          HUTCHMED (China) Limited

 b)   LEI                                                           2138006X34YDQ6OBYE79

 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument   ADS each representing five Ordinary Shares of US$0.10 each

      Identification code

                                                                    ADS ISIN: US44842L1035

 b)   Nature of the transaction                                     Sale of 3,000 ADSs on September 12, 2023 at a price of US$14.70 per ADS.

 c)   Price(s) and volume(s)
                                                                                         Price(s)             Volume(s)
                                                                                         US$14.70             3,000 ADSs

 d)   Aggregated information     N/A

      - Aggregated volume
      - Price

 e)   Date of the transaction    2023-09-12

 f)   Place of the transaction   Nasdaq Stock Market

 

N/A

 

e)

 

Date of the transaction

 

2023-09-12

 

 

f)

 

Place of the transaction

 

Nasdaq Stock Market

 

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. It has approximately
5,000 personnel across all its companies, at the center of which is a team of
about 1,800 in oncology/immunology. Since inception, it has focused on
bringing cancer drug candidates from in-house discovery to patients around the
world, with its first three oncology drugs now approved and marketed in China.
For more information, please visit: www.hutch‑med.com
(https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

Contacts
 Investor Enquiries
 Mark Lee, Senior Vice President                   +852 2121 8200
 Annie Cheng, Vice President                       +1 (973) 306 4490

 Media Enquiries
 Ben Atwell / Alex Shaw,                           +44 20 3727 1030 / +44 7771 913 902 (Mobile) /

                                                 +44 7779 545 055 (Mobile)
 FTI Consulting
HUTCHMED@fticonsulting.com
 Zhou Yi,                                          +852 9783 6894 (Mobile)

HUTCHMED@brunswickgroup.com
 Brunswick

 Nominated Advisor
 Atholl Tweedie / Freddy Crossley / Daphne Zhang,  +44 (20) 7886 2500

Panmure Gordon

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHNKQBBOBKKKCD